Cancer Genes and Genomics Deletion or Epigenetic Silencing of AJAP 1 on 1 p 36 in Glioblastoma

Glioblastoma is universally fatal because of its propensity for rapid recurrence due to highlymigratory tumor cells. Unraveling the genomic complexity that underlies this migratory characteristic could provide therapeutic targets that would greatly complement current surgical therapy. Using multiple high-resolution genomic screening methods, we identified a single locus, adherens junctional associated protein 1 (AJAP1) on chromosome 1p36 that is lost or epigenetically silenced in many glioblastomas. We found AJAP1 expression absent or reduced in 86% and 100% of primary glioblastoma tumors and cell lines, respectively, and the loss of expression correlates with AJAP1 methylation. Restoration of AJAP1 gene expression by transfection or demethylation agents results in decreased tumor cell migration in glioblastoma cell lines. This work shows the significant loss of expression of AJAP1 in glioblastoma and provides evidence of its role in the highlymigratory characteristic of these tumors.Mol Cancer Res;

[1]  L. Loeb,et al.  Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.

[2]  K. Bélanger,et al.  Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. , 1997, Anti-cancer drugs.

[3]  F. Lazeyras,et al.  Possible efficacy of temozolomide in a patient with gliomatosis cerebri , 2001, Neurology.

[4]  M. Westphal,et al.  Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Erwin G. Van Meir,et al.  Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. , 2004, The American journal of pathology.

[6]  H. Ng,et al.  Identification of two contiguous minimally deleted regions on chromosome 1p36.31–p36.32 in oligodendroglial tumours , 2004, British Journal of Cancer.

[7]  D. Brat,et al.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. , 2004, Neuro-oncology.

[8]  M. West,et al.  Gene expression profiling and genetic markers in glioblastoma survival. , 2005, Cancer research.

[9]  R. Kiss,et al.  Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Parrett,et al.  Digital karyotyping technology: exploring the cancer genome , 2005, Expert review of molecular diagnostics.

[11]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[12]  S. Gregory,et al.  Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma , 2005, Oncogene.

[13]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[14]  A. Starzinski-Powitz,et al.  Targeting of transmembrane protein shrew-1 to adherens junctions is controlled by cytoplasmic sorting motifs. , 2006, Molecular biology of the cell.

[15]  Tae-You Kim,et al.  Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. , 2006, Cancer research.

[16]  M. Esteller,et al.  Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme , 2007, Journal of Neuro-Oncology.

[17]  K. Aldape,et al.  The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration , 2006, Cancer biology & therapy.

[18]  D. Louis,et al.  Downregulation of RUNX3 and TES by hypermethylation in glioblastoma , 2007, Oncogene.

[19]  M. Ruonala,et al.  Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. , 2007, Molecular biology of the cell.

[20]  Gabriele Schackert,et al.  CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. , 2007, Carcinogenesis.

[21]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[22]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[23]  J. Maris,et al.  CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas , 2008, Journal of the National Cancer Institute.

[24]  P. Lichter,et al.  Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma , 2009, Genes, chromosomes & cancer.

[25]  J. Uhm Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[26]  Darell D. Bigner,et al.  Glioblastoma Multiforme Oncogenomics and Signaling Pathways , 2009, Clinical medicine. Oncology.

[27]  L. Cope,et al.  Digital Karyotyping , 2012, Molecular Diagnosis & Therapy.